临床终点
临床试验
医学
终点测定
临床肿瘤学
肿瘤科
代理终结点
内科学
重症监护医学
癌症
医学物理学
作者
Saadettin Kılıçkap,Umut Demırcı,Nuri Karadurmuş,Mutlu Doğan,Bülent Akıncı,Mehmet Alı Nahıt Şendur
出处
期刊:PubMed
日期:2018-12-01
卷期号:23 (7): 1-6
被引量:12
摘要
In oncology clinical trials, many different endpoints can be used as primary or secondary endpoints. Advances in cancer treatment have provided longer survival outcomes, particularly in certain types of cancer. Overall survival is accepted as the gold standard endpoint for demonstrating clinical benefit; however, it is associated with some disadvantages such as requirement of long-term follow-up, requirement of higher number of patients, and high cost. Thus, the question "what is the most appropriate endpoint in clinical trials?" comes to mind. The present review discusses the endpoints in oncology clinical trials.
科研通智能强力驱动
Strongly Powered by AbleSci AI